Lasmiditan in patients with common migraine comorbidities: a post hoc efficacy and safety analysis of two phase 3 randomized clinical trials
2020 ◽
Vol 36
(11)
◽
pp. 1791-1806
◽
Keyword(s):
Phase 3
◽
2018 ◽
Vol 19
(3)
◽
pp. 457-457
◽
Keyword(s):
2015 ◽
Vol 74
(Suppl 2)
◽
pp. 1180.3-1181